Postmarketing Safety: US FDA ‘Best Practices’ Include Weekly Adverse Event Screening For New Drugs

Agency’s approach to risk-based postmarketing safety surveillance explained in new draft document issued under the 21st Century Cures Act; product characteristics and intended use guide the frequency and extent of adverse event report screening, with newer drugs undergoing weekly reviews for three years after approval.

Laptop computer with magnifying glass, concept of search
US FDA takes a close look at adverse event reports every week for newly approved drugs. • Source: Shutterstock

The US Food and Drug Administration’s risk-based approach to postmarketing drug safety monitoring entails weekly screening of individual adverse event reports for three years after approval of certain drugs and biologics, the agency explains in a new draft document.

Products receiving weekly screening during their first three years on the market include: new molecular entities, novel biologics, biosimilars, and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Safety

More from Pink Sheet